Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparison between CD19 and CD20 expression patterns on acute leukemic cells.

Bo-Tao Ning1, Yong-Min Tang, Ying-Hu Chen

  • 1Department of Hematology and Oncology, The Children's Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|January 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric candidemia epidemiology and antifungal susceptibility profiles reported by the ISPED program in China, 2016-2024.

Antimicrobial agents and chemotherapy·2026
Same author

Molecular epidemiology of viral enteric in children in Hangzhou.

BMC infectious diseases·2025
Same author

Twenty years' development and application of flow cytometry.

World journal of pediatrics : WJP·2025
Same author

[Clinical Characteristics and Prognostic Analysis of Childhood Acute Lymphoblastic Leukemia with Positive <i>E2A-PBX1</i> Fusion Gene].

Zhongguo shi yan xue ye xue za zhi·2025
Same author

Challenges and overcoming strategies in CAR-T cell therapy for pediatric neuroblastoma.

World journal of pediatrics : WJP·2025
Same author

Expert consensus for pertussis in children: new concepts in diagnosis and treatment.

World journal of pediatrics : WJP·2024
Same journal

[Research Progress on the Bone Marrow Microenvironment in Beta-Thalassemia --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of CAR-T Cell Therapy in Autoimmune Diseases --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress in Venetoclax-Based Combination Therapy in Acute Myeloid Leukaemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Advances in the Treatment of Acute Myeloid Leukemia with <i>TP53</i> Mutations-Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Analysis of Risk Factors and Clinical Characteristics of Early Death in Patients with Hemophagocytic Syndrome].

Zhongguo shi yan xue ye xue za zhi·2026
See all related articles

CD19 is a superior antibody target for B-lineage acute leukemias compared to CD20. This study demonstrates CD19

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Antibody-based therapies are crucial for treating B-lineage acute leukemias.
  • Identifying optimal molecular targets is essential for improving therapeutic efficacy.
  • CD19 and CD20 are B-cell surface antigens often targeted in leukemia treatment.

Purpose of the Study:

  • To compare the expression patterns and suitability of CD19 and CD20 as antibody targets in B-lineage acute leukemias.
  • To provide evidence supporting CD19 as a more effective target molecule than CD20.

Main Methods:

  • Multi-parameter flow cytometry was used to immunophenotype leukemia cells from 321 acute leukemia patients.
  • Analysis focused on CD45/SSC gating and the expression levels of CD19 and CD20.
  • Statistical analyses were performed to compare antigen expression rates, fluorescence intensity, sensitivity, and specificity.

Related Experiment Videos

Main Results:

  • CD19 showed significantly higher positive rates (99.1% in B-lineage ALL, 100% in B/My AMLL) compared to CD20 (28.4% and 29.4%, respectively).
  • CD19 expression was consistently high across B-lineage subtypes, while CD20 expression was limited.
  • CD19 demonstrated significantly higher sensitivity (99.2% vs. 28.6%) for B-lineage leukemias compared to CD20, with comparable specificity.

Conclusions:

  • CD19 exhibits continuous and homogeneous expression on nearly all B-lineage leukemic cells, making it a highly reliable target.
  • CD19's superior sensitivity and broad reactivity pattern suggest it is a better antibody targeting molecule than CD20 for B-lineage acute leukemias.
  • These findings support the use of CD19-targeted therapies for improved treatment outcomes in B-lineage acute leukemia.